Clarifying the Optimal Application of SLT Therapy Trial

Recruiting now · Phase 3

Conditions studied: Glaucoma and Ocular Hypertension

In brief

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Key facts

Study ID

NCT04967989

Run by

University of Pittsburgh

People needed

790

Starts

2021-09-07

Expected to finish

2027-08-31

Last updated by the study team

2025-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older and in good health
• Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
• High-risk ocular hypertension (OHT): IOP > 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of >0.2 between eyes)
• Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° <15 dB (see figure on next page)
• Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points <15 dB or mean deviation -12.0 dB or better with 1 central 5° points <15 dB (see figure on next page).
• Each eye with BCVA 20/200 (UK 6/60) or better

You may not qualify if…

• Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)
• Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure
• Advanced POAG in either eye (worse than moderate POAG as defined above)
• Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
• Mean IOP > 35 mmHg at either the screening or baseline visit in either eye
• Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
• Contraindications to SLT or any other study intervention
• Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
• Any intraocular surgical procedure within the past 6 months in either eye
• Inability to attend all scheduled study visits
• Pregnant or planning to become pregnant in the next 4 years

Where it is running

• Harvard Eye Associates — Laguna Hills, California, United States (enrolling)
• Doheny Eye Center UCLA — Pasadena, California, United States (enrolling)
• University of California, Davis — Sacramento, California, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• Mile High Eye Institute — Sheridan, Colorado, United States (enrolling)
• Clear Vue Laser Eye Center — Lakeworth, Florida, United States (enrolling)
• Northwestern Medical Group — Chicago, Illinois, United States (enrolling)
• Chicago Arbor Eye Institute — Orland Park, Illinois, United States (enrolling)
• Illinois Eye Center — Peoria, Illinois, United States (enrolling)
• Wilmer Eye Institute Johns Hopkins — Baltimore, Maryland, United States (enrolling)
• Massachusetts Eye and Ear — Boston, Massachusetts, United States (enrolling)
• Ophthalmic Consultants of Boston — Boston, Massachusetts, United States (enrolling)
• Mark Latina, LLC — Reading, Massachusetts, United States (enrolling)
• University of Michigan Kellogg Eye Center — Ann Arbor, Michigan, United States (enrolling)
• Kresge Eye Institute Wayne State University — Detroit, Michigan, United States (enrolling)
• New York Eye Surgery Associates — The Bronx, New York, United States (enrolling)
• University Hospitals Eye Institute — Cleveland, Ohio, United States (enrolling)
• Cleveland Clinic Cole Eye Institute — Cleveland, Ohio, United States (enrolling)
• Devers Eye Institute — Portland, Oregon, United States (enrolling)
• Eye Care Specialists — Kingston, Pennsylvania, United States (enrolling)
• Scheie Eye Institute — Philadelphia, Pennsylvania, United States (enrolling)
• Wills Eye Hospital — Philadelphia, Pennsylvania, United States (enrolling)
• West Virginia University — Morgantown, West Virginia, United States (enrolling)
• University of Wisconsin-Madison — Madison, Wisconsin, United States (enrolling)
• Vanderbilt Eye Institute — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.